Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Doxazosin for the treatment of nightmare disorder: A diary-based case study.

Ståle Pallesen, Hilde Sofie Hamre, Nina Lang, Bjørn Bjorvatn

SAGE open medical case reports January 1, 2020 DOI: 10.1177/2050313x20936079 (opens in new tab) via PubMed

Summary

AI-generated from the abstract

A patient who developed severe nightmares after an erroneous adrenaline injection tracked their sleep for 280 days while taking 0, 4, or 8 mg of the α1-adrenergic antagonist doxazosin. The 8 mg dose resulted in 55.2% nightmare-free nights, far exceeding the 4.3% nightmare-free nights without the drug (odds ratio = 28.2). Dizziness was reported but not bothersome. The findings suggest doxazosin may help treat posttraumatic stress disorder-related nightmares.

Study at a glance

Characteristics Case study Randomized Case report Peer reviewed
Sample size 1
Population Patient with severe nightmares following erroneous medical administration of adrenaline
Intervention doxazosin
Dose 0, 4, or 8 mg
Duration 280 days
Keywords Doxazosin Nightmare disorder Treatment Α1-adrenergic antagonist
Key finding 8 mg doxazosin was associated with 55.2% nightmare-free nights compared to 4.3% without the drug.

Abstract

The α1-adrenergic antagonist prazosin has showed good effect against posttraumatic stress disorder-related nightmares in several randomized controlled trials. The α1-adrenergic antagonist doxazosin, which has a longer half-live than prazosin, has received far less attention in the treatment of such nightmares. Here, we report a case of a patient suffering from severe nightmares following an erroneous medical administration of adrenaline (causing severe physiological hyper-activation) who was treated with doxazosin. Over a period of 280 days, the patient kept a nightmare diary and took 0, 4, or 8 mg doxazosin. The analyses showed that 8 mg doxazosin (55.2% nightmare-free nights) worked better (odds ratio = 28.2; 95% confidence interval = 3.7-213.9) compared to nights without doxazosin (4.3% nightmare-free nights). Except dizziness, which was not regarded as particularly bothersome by the patient, doxazosin was well tolerated. It is concluded that doxazosin may be indicated as a pharmacological treatment for patients suffering from posttraumatic stress disorder-related nightmares.

Comments

No comments yet.

Log in to comment